Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512573 · ClinicalTrials.gov registry record
Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)
A clinical trial, sponsored by CorEvitas.
- Completed
- Registry status
- 232
- Enrollment target
NCT04512573: Completed study, sponsored by CorEvitas.
NCT04512573 is a clinical trial that has completed, run by CorEvitas. The registered enrollment target is 232 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04512573 has completed, sponsored by CorEvitas.
- COMPLETED
- Registry status
- 232 participants
- Enrollment target
Study Summary
This is a prospective, real-world observational study in which patients with RA who are initiating treatment with a JAK inhibitor medication will self-report disease activity and treatment satisfaction measures using their own web-enabled device such as a smartphone. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Primary Outcome
To analyze self-reported disease activity and treatment satisfaction for patients with RA in the real world at the time of initiation with a JAK inhibitor medication.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2022-08-31 |
What the finished NCT04512573 record still lists
NCT04512573 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04512573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04512573 about?
NCT04512573 is a clinical study titled "Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)". This is a prospective, real-world observational study in which patients with RA who are initiating treatment with a JAK inhibitor medication will self-report disease activity and treatment satisfaction measures using their own web-enabled device such as a smartphone. Secondary objectives include ana...
What is the current status of trial NCT04512573?
This trial is currently completed. The enrollment target is 232 participants. The study started on 2020-05-21. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT04512573?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI